SCHEDULE 13G/A: Nantahala Capital Management Reports 5.6% Beneficial Stake in Soleno Therapeutics

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a 5.6% beneficial ownership stake in Soleno Therapeutics, Inc. as of March 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed an Amendment No. 8 to Schedule 13G.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 2,627,651 shares of Soleno Therapeutics, Inc. Common Stock.
• This ownership represents 5.6% of the total outstanding shares of Soleno Therapeutics, Inc., based on 45,857,291 shares outstanding as reported by the issuer on Form 10-K on February 28, 2025.
• The 2,627,651 shares include 870,628 shares that may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• The Reporting Persons hold shared voting and shared dispositive power over all 2,627,651 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates an institutional investor holds a significant stake, which can be seen as a vote of confidence. However, it's a routine disclosure without new operational or financial details.

Positives

• A significant beneficial ownership stake (5.6%) by an institutional investor like Nantahala Capital Management can be viewed as a vote of confidence in Soleno Therapeutics, Inc.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, which may reduce concerns about activist intervention.

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm in a publicly traded biotechnology company. It reflects an investment position rather than a strategic industry move or operational update.

Stakeholder Impact

• Shareholders: May view the significant stake by an institutional investor as a positive signal regarding the company's prospects, potentially increasing investor confidence.

Key Dates

Keywords

Soleno Therapeutics, Nantahala Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology, Pharmaceuticals